<DOC>
	<DOCNO>NCT01095809</DOCNO>
	<brief_summary>The purpose study determine whether intravitreous bevacizumab intravitreous triamcinolone acetonide effective safe treatment uveitic macular oedema</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Repeated Dosis Intravitreous Bevacizumab Uveitic Macular Oedema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>adult patient uveitis retinal vasculitis unilateral bilateral macular oedema macular thickness &gt; 250 micra use OCT visual acuity least 20/200 stable treatment oral prednisone least 3 month , either oral ciclosporin immunomodulator treat intraocular inflammatory disease patient follow study 's requirement patient consent participate presence corneal crystalline opacity prevent observation fundus eye patient require ocular surgery next 3 month oneeyed pregnancy child breastfeed previous history glaucoma treatment woth experimental ocular drug previous thromboembolism receive oral anticoagulant treatment vitrectomy patient prove tractional macular pathology associate macular oedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>